Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis.
Al-Odat OS, Elbezanti WO, Gowda K, Srivastava SK, Amin SG, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK. Al-Odat OS, et al. Among authors: srivastava sk. Front Pharmacol. 2024 Oct 1;15:1436786. doi: 10.3389/fphar.2024.1436786. eCollection 2024. Front Pharmacol. 2024. PMID: 39411073 Free PMC article.
Bruton's Tyrosine Kinase Targeting in Multiple Myeloma.
Von Suskil M, Sultana KN, Elbezanti WO, Al-Odat OS, Chitren R, Tiwari AK, Challagundla KB, Srivastava SK, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK. Von Suskil M, et al. Among authors: srivastava sk. Int J Mol Sci. 2021 May 27;22(11):5707. doi: 10.3390/ijms22115707. Int J Mol Sci. 2021. PMID: 34071917 Free PMC article. Review.
Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma.
Al-Odat O, von Suskil M, Chitren R, Elbezanti W, Srivastava S, Budak-Alpddogan T, Jonnalagadda S, Aggarwal B, Pandey M. Al-Odat O, et al. Front Pharmacol. 2021 Jul 19;12:699629. doi: 10.3389/fphar.2021.699629. eCollection 2021. Front Pharmacol. 2021. PMID: 34349655 Free PMC article. Review.
Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells.
Elbezanti WO, Al-Odat OS, Chitren R, Singh JK, Srivastava SK, Gowda K, Amin S, Robertson GP, Nemmara VV, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK. Elbezanti WO, et al. Among authors: srivastava sk. Front Pharmacol. 2022 Sep 9;13:894535. doi: 10.3389/fphar.2022.894535. eCollection 2022. Front Pharmacol. 2022. PMID: 36160379 Free PMC article.
1,335 results